A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
- Resource Type
- Article
- Source
- Targeted Oncology; Jul2023, Vol. 18 Issue 4, p517-530, 14p
- Subject
- Language
- ISSN
- 17762596